EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK

被引：2
|
作者：
Hanna, Jerome [1 ]
Rosen, Jan Paul [1 ]
Smethurst, Caroline [1 ]
机构：
[1] Biogen Idec Ltd, Maidenhead, Berks, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2013年 / 84卷 / 11期
关键词：
D O I：
10.1136/jnnp-2013-306573.179
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of natalizumab as escalation and de-escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, N.
    Kollia, K.
    Katsarava, Z.
    Weber, R.
    Igwe, E.
    Woods, S.
    Diener, H.
    MULTIPLE SCLEROSIS, 2007, 13 : S170 - S171
  • [22] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
    Huntemann, Niklas
    Mueller, Marc
    Masanneck, Lars
    Baumgart, Romy
    Axhausen, Franziska
    Wolff, Stephanie
    Kutsojannis, Bela
    Koelsche, Tristan
    Korsen, Melanie
    Pfeuffer, Steffen
    Meuth, Sven
    Pawlitzki, Marc
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
  • [23] Natalizumab is associated with a reduction in relapse-related hospitalisations and steroid treatment in relapsing-remitting multiple sclerosis patients enrolled in the TYSABRI® Observational Program
    Trojano, M.
    Spelman, T.
    Butzkueven, H.
    Kappos, L.
    Wiendl, H.
    Chang, I.
    Naoshy, S.
    Ho, P. -R.
    Licata, S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 290 - 291
  • [24] Characteristics of real-world disability improvement in relapsing-remitting multiple sclerosis patients treated with natalizumab in the TYSABRI® Observational Program
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Spelman, T.
    Trojano, M.
    Dong, Q.
    Campbell, N.
    Ho, P. -R.
    Licata, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 373 - 373
  • [25] The societal impact of treatment with natalizumab of relapsing-remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study
    Polistena, B.
    Spandonaro, F.
    Capra, R.
    Fantaccini, S.
    Santoni, L.
    Zimatore, G. B.
    Gasperini, C.
    Amato, M. P.
    Bertolotto, A.
    Cargnelutti, D.
    Centonze, D.
    Comi, G.
    Cottone, S.
    Deotto, L.
    Florio, C.
    Gallo, P.
    Ghezzi, A.
    Granella, F.
    Malentacchi, G. M.
    Mancardi, G. L.
    Marrosu, G. M.
    Morra, V. B.
    Montanari, E.
    Nichelli, P.
    Savettieri, G.
    Tedeschi, G.
    Tola, M. R.
    Trojano, M.
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019,
  • [26] THE SOCIETAL IMPACT OF NATALIZUMAB TREATMENT IN THE ITALIAN RELAPSING-REMITTING MULTIPLE SCLEROSIS CLINICAL PRACTICE: THE TYSABRI PHARMACOECONOMICS (TYPE) STUDY
    Polistena, B.
    Spandonaro, F.
    Gasperini, C.
    Gb, Zimatore
    Santoni, L.
    Fantaccini, S.
    Capra, R.
    VALUE IN HEALTH, 2016, 19 (07) : A434 - A434
  • [27] Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
    Sangalli, F.
    Moiola, L.
    Bucello, S.
    Annovazzi, P.
    Rizzo, A.
    Radaelli, M.
    Vitello, G.
    Grimaldi, L. M. E.
    Ghezzi, A.
    Martinelli, V.
    Comi, G.
    NEUROLOGICAL SCIENCES, 2011, 31 : S299 - S302
  • [28] Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study
    Baldi, Eleonora
    Guareschi, Angelica
    Vitetta, Francesca
    Senesi, Caterina
    Curti, Erica
    Montepietra, Sara
    Simone, Anna Maria
    Immovilli, Paolo
    Caniatti, Luisa
    Tola, Maria Rosaria
    Pesci, Ilaria
    Montanari, Enrico
    Sola, Patrizia
    Granella, Franco
    Motti, Luisa
    Ferraro, Diana
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (09) : 1849 - 1855
  • [29] Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis
    Guarnera, Cristina
    Bramanti, Placido
    Mazzon, Emanuela
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2193 - 2207
  • [30] Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Kalincik, T.
    Horakova, D.
    Spelman, T.
    Jokubaitis, V.
    Trojano, M.
    Lugaresi, A.
    Izquierdo, G.
    Rozsa, C.
    Grammond, P.
    Alroughani, R.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Lechner-Scott, J.
    Slee, M.
    Fernandez-Bolanos, R.
    Grand'Maison, F.
    Hupperts, R.
    Verheul, F.
    Hodgkinson, S.
    Oreja-Guevara, C.
    Spitaleri, D.
    Barnett, M.
    Terzi, M.
    Bergamaschi, R.
    McCombe, P.
    Sanchez-Menoyo, J.
    Simo, M.
    Csepany, T.
    Rum, G.
    Boz, C.
    Havrdova, E.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 195 - 196
12345